CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Liquid peanut extract (Peanut SLIT)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01373242
NCT01373242Phase 2Completed
CompareCT.gov

Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy}

University of North Carolina, Chapel Hill·interventional·Posted Jun 14, 2011·Updated Jun 12, 2019

In Brief

A Phase 2 clinical trial evaluating Liquid peanut extract (Peanut SLIT) for Peanut Hypersensitivity and 3 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after treatment has been discontinued (tolerance).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH)

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2011
Enrollment StartJun 1, 2011
Primary CompletionApr 16, 2018
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 15.0 years ago

Interventions

Liquid peanut extract (Peanut SLIT)drug

Liquid peanut extract will be administered under the tongue